The Food and Drug Administration approved Pfizer’s nasal spray for migraines, giving patients access to a potentially fast-acting pain relief option, writes NBC NEWS.

The drug, Zavzpret, also known as zavegepant, was approved for the treatment of acute migraine with or without aura in adults, the company said. Aura refers to any neurological disturbance that appears shortly before or during the development of migraines.

Pfizer gained the drug, as well as the FDA-approved oral migraine pill Nurtec ODT, through its USD 11.6 billion buyout of Biohaven Pharmaceuticals last year.

The drug, whose pricing will be revealed at its launch in July, is “expected to be comparable in price to other FDA approved migraine medicines” which belong to the same class, Pfizer told Reuters.

Zavzpret belongs to a class of drugs called calcitonin gene-related peptide inhibitors and will compete with other therapies from AbbVie, Eli Lilly, Amgen and Teva Pharmaceutical.